BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewsWire • 05/14/24
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024GlobeNewsWire • 05/07/24
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple TumorsGlobeNewsWire • 05/06/24
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/24/24
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ProgressGlobeNewsWire • 03/26/24
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024GlobeNewsWire • 03/19/24
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/07/24
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor TypesGlobeNewsWire • 12/13/23
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023GlobeNewsWire • 12/06/23
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL EventGlobeNewsWire • 12/05/23
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent ProgressGlobeNewsWire • 11/07/23
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023GlobeNewsWire • 10/10/23
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23